202 related articles for article (PubMed ID: 19388929)
1. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
3. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Feng R; Anderson G; Xiao G; Elliott G; Leoni L; Mapara MY; Roodman GD; Lentzsch S
Blood; 2007 Mar; 109(5):2130-8. PubMed ID: 17095620
[TBL] [Abstract][Full Text] [Related]
4. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
5. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib inhibits human osteoclastogenesis.
von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
[TBL] [Abstract][Full Text] [Related]
7. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
He J; Liu Z; Zheng Y; Qian J; Li H; Lu Y; Xu J; Hong B; Zhang M; Lin P; Cai Z; Orlowski RZ; Kwak LW; Yi Q; Yang J
Cancer Res; 2012 Dec; 72(24):6393-402. PubMed ID: 23066034
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
10. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Yaccoby S; Pearse RN; Johnson CL; Barlogie B; Choi Y; Epstein J
Br J Haematol; 2002 Feb; 116(2):278-90. PubMed ID: 11841428
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Terpos E
Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
[No Abstract] [Full Text] [Related]
12. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
Pennisi A; Ling W; Li X; Khan S; Wang Y; Barlogie B; Shaughnessy JD; Yaccoby S
PLoS One; 2010 Dec; 5(12):e15233. PubMed ID: 21188144
[TBL] [Abstract][Full Text] [Related]
13. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis.
Hsieh TP; Sheu SY; Sun JS; Chen MH
Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188
[TBL] [Abstract][Full Text] [Related]
14. Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts.
Zhang T; Han W; Zhao K; Yang W; Lu X; Jia Y; Qin A; Qian Y
FASEB J; 2019 Apr; 33(4):5399-5410. PubMed ID: 30702934
[TBL] [Abstract][Full Text] [Related]
15. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
16. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Chauhan D; Munshi NC; Richardson PG; Anderson KC
Br J Haematol; 2007 Oct; 139(1):55-63. PubMed ID: 17854307
[TBL] [Abstract][Full Text] [Related]
17. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
[TBL] [Abstract][Full Text] [Related]
18. Osteoblastogenesis and tumor growth in myeloma.
Yaccoby S
Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
Ishida M; Shen WR; Kimura K; Kishikawa A; Shima K; Ogawa S; Qi J; Ohori F; Noguchi T; Marahleh A; Kitaura H
Biomed Pharmacother; 2019 Jan; 109():242-253. PubMed ID: 30396082
[TBL] [Abstract][Full Text] [Related]
20. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
